Click on the links below to view publications of interest to you. You can also
search our publications database by author, keyword(s), date of publication,
journal or other parameters. Or, download our bibliography.
Clinical Validation
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
N Engl J Med. 2004;351(27):2817-2826.
A Population-Based Study of Tumor Gene Expression and Risk of Breast Cancer Death Among Lymph Node-Negative Patients
LA Habel, S Shak, M Jacobs, A Capra, C Alexander, M Pho, J Baker, MG Walker, D Watson, J Hackett, N Blick, D Greenberg, L Fehrenbacher, B Langholz, CP Quesenberry
Breast Cancer Res. 2006;8(3):R25.
Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, G Tang, S Shak, C Kim, J Baker, W Kim, M Cronin, FL Baehner, D Watson, J Bryant, JP Costantino, C Geyer Jr., DL Wickerham, N Wolmark
J Clin Oncol. 2006;24(23):3726-3734.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer
K Albain, W Barlo, S Shak, G Hortobagyi, R Livingston, I-T Yeh, P Ravdin,R Bugarini, FL Baehner, NE Davidson, GW Sledge, E Winer, C Hudis, JIngle, E Perez, K Pritchard, L Shepherd, J Gralow, C Yoshizawa, D Allred, C Osborne, D Hayes
Lancet Oncology. 2009.
Decision Impact
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20.
Eleftherios P. Mamounas,*Gong Tang, Bernard Fisher, Soonmyung Paik, Steven Shak, Joseph P. Costantino, Drew Watson, Charles E. Geyer Jr, D. Lawrence Wickerham, and Norman Wolmark
J Clin Oncol. 2010.
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.
Shelly S. Lo,*Patricia B. Mumby, John Norton, Karen Rychlik, Jeffrey Smerage, Joseph Kash, Helen K. Chew, Ellen R. Gaynor, Daniel F. Hayes, Andrew Epstein, and Kathy S. Albain
J Clin Oncol. 2010.
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
R Oratz, D Paul, AL Cohn, SM Sedlacek
J Oncol Pract. 2007;3(4):182-186.
Neoadjuvant Treatment
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women with Locally Advanced Breast Cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, J Wu, G Mariani, J Rodriguez, M Carcangiu, D Watson, P Valagussa, R Rouzier, WF Symmans, JS Ross, GN Hortobagyi, L Pusztai, S Shak
J Clin Oncol. 2005;23(29):7265-7277.
Health Economics
Economic Analysis of Targeting Chemotherapy Using a 21-Gene RT-PCR Assay in Lymph Node-Negative, Estrogen Receptor-Positive, Early-Stage Breast Cancer
J Hornberger, LE Cosler, GH Lyman
Am J Manag Care. 2005;11(5):313-324.
Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer, An Economic Analysis Based on Prognostic and Predictive Validation Studies
GH Lyman, LE Cosler, NM Kuderer, J Hornberger
Cancer. 2007;109(6):1011-1018.
Platform Technology
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
M Cronin, M Pho, D Dutta, JC Stephans, S Shak, MC Kiefer, JM Esteban, JB Baker
Am J Pathol. 2004;164(1):35-42.
Analytical Validation of the Oncotype DX Genomic Diagnostic Test Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer
M Cronin, C Sangli, ML Liu, M Pho, D Dutta, A Nguyen, J Jeong, J Wu, KC Langone, D Watson
Clin Chem. 2007;53(6):1084-1091.
Biomarker discovery for colon cancer using a 761 gene RT-PCR assay
Kim M Clark-Langone*1, Jenny Y Wu1, Chithra Sangli1, Angela Chen1,James L Snable1, Anhthu Nguyen1, James R Hackett1,Joffre Baker1,Greg Yothers2, Chungyeul Kim2 and Maureen T Cronin1
BMC Genomics. 2007;8(279):1471-2164-8-279.
Assay Development
Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
FJ Esteva, AA Sahin, M Cristofanilli, K Coombes, SJ Lee, J Baker, M Cronin, MG Walker, D Watson, S Shak, GN Hortobagyi
Clin Cancer Res. 2005;11(9):3315-3319.
Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes
MA Cobleigh, B Tabesh, P Bitterman, J Baker, M Cronin, ML Liu, R Borchik, JM Mosquera, MG Walker, S Shak
Clin Cancer Res. 2005;11(24 Pt 1):8623-8631.
Additional Oncotype DX Assay-Related Articles
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, MR Somerfield, DF Hayes, RC Bast Jr.
J Clin Oncol. 2007;25(33):5287-5312.
Adjuvant Chemotherapy for Patients with Estrogen Receptor-Positive Breast Cancer
HJ Burstein, S Paik, P Ravdin, K Albain
ASCO Educational Book. 2006.
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
R Simon
J Clin Oncol. 2005;23(29):7332-7341.
Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
S Paik
Oncologist. 2007;12(6):631-635.
Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
SS Badve, FL Baehner, RP Gray, BH Childs, T Maddala, ML Liu, SC Rowley, S Shak, ED Perez, LJ Shulman, S Martino, NE Davidson, GW Sledge, LJ Goldstein, JA Sparano
J Clin Oncol. 2008;26:2473-2481.
Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer
DC Allred
J Clin Oncol. 2008;25(15):2433-2435.
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
JA Sparano, S Paik
J Clin Oncol. 2008;26:721-728.
TAILORx Trial Articles
The TAILORx Trial: Individualized Options for Treatment
JA Sparano
Commun Oncol. 2006;3:494-496.
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
JA Sparano
Clin Breast Cancer. 2006;7(4):347-350.
Design of and Rationale for the Trial Assigning Individualized Options for Treatment (TAILORx)
JA Sparano
ASCO Educational Book. 2007.
Scientific Presentations, Posters & Abstracts
2009 SABCS---San Antonio, TX
Abstract #112
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne
CK, Hayes DF, For The Breast Cancer Intergroup of North America Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL
Abstract #2031
Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
Oratz R, Chao C, Skrzypczak S, Kim B, Broder M New York University School of Medicine, New York, NY; Genomic Health, Inc., Redwood City, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Pardee RAND Graduate School, RAND Corporation, Santa Monica, CA; Partnership for Health Analytic Research, Beverly Hills, CA
Abstract #5165
Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways.
Sparano JA, Gray R, Goldstein LJ, Childs BH, Brassard D, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL, Kenny P, Perez EA, Shulman LN, Martino S, Sledge GW, Davidson NE Eastern Cooperative Oncology Group, Brookline, MA; Sanofi-Aventis, Inc., Bridgewater, NJ; Genomic Health, Inc., Redwood City, CA; North Central Cancer Treatment Group, Rochester, MN; Cancer and Leukemia Group B, Chicago, IL; Southwest Oncology Group, Ann Arbor, MI
Abstract #6004
HER2 Amplification, Polysomy Status and Breast Cancer Survival in a Large Kaiser Permanente Case-Control Study: Assessment of HER2 by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Fluorescence In
Situ Hybridization (FISH).
Baehner FL, Achacoso N, Maddala T, Alexander C, Shak S, Quesenberry CP, Habel LA University of California, San Francisco, San Francisco, CA; Kaiser Permanente Northern
California, Oakland, CA; Genomic Health, Redwood City, CA
Abstract #6021
Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.
Anderson JM, Shak S, Millward C, Labusch M, Chen I, Watson D, Baehner FL Genomic Health, Inc., Redwood City, CA
2009 ASCO Breast Meeting - San Francisco, CA
Abstract # 64
Biopsy Cavities in Breast Cancer Specimens: Their Impact on Quantitative RT-PCR Gene Expression Profiles and Recurrence Risk Assessment
FL Baehner, C. Quale, D. Cherbavaz, C. Sangli, C. Pomeroy, A. Chen, F. Lane, L. Intagliatta, A. Goddard, S. Shak; University of California, San Francisco, Redwood City, CA; Genomic Health, Redwood City, CA
ASCO 2009 Abstract #4000
A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study
D. Kerr, R. Gray, P. Quirke, D. Watson, G. Yothers, I. C. Lavery, M. Lee, M. J. O'Connell, S. Shak, N. Wolmark and the Genomic Health & QUASAR Colon Teams; University of Oxford, Oxford, UK; Birmingham Clinical Trials Unit, Birmingham, UK; Leeds Institute of Molecular Medicine, Leeds, UK; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA; Cleveland Clinic Foundation (CCF), Cleveland, OH; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA
2009 ASCO Annual Meeting― Orlando, FL
Abstract # 500
Genotypic characterization of phenotypically defined triple-negative breast cancer
J. A. Sparano, L. J. Goldestin, B. H. Childs, S. Shak, S. Badve, F. L. Baehner
Abstract # 549
Molecular characterization of male breast cancer by standardized quantitative RTPCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers.
S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, G. W. Sledge
2009 Kyoto Breast Cancer Consensus Conference International Convention Kyoto, Japan
Abstract
The First Report Of The Association Between The Recurrence Score And The Risk Of Recurrence In A Japanese Population
M. Toi, H. Iwata, N. Masuda, S. Ohno, S. Namakura, Y.Yamanaka, T. Nakayama, M. Kashiwaba, S, Kamigaki, K. Aogi, T. Ueno, K. Kuroi.
2009 United States and Canadian Academy of Pathology (USCAP) Annual Meeting Boston, MA
Abstract # 1421
HER2 Concordance between Central Laboratory Immunohistochemistry, FISH and Quantitative RT-PCR in Intergroup Trial E2197
Baehner FL, Gray R, Maddala T, Childs B, Rowley S, Shak S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA, Badve S
Abstract # 1574
Biopsy Cavities in Breast Cancer Specimens: Impact on Quantitative RT-PCR Gene Expression Profiles and Recurrence Risk Assessment
FL Baehner, C Quale, C Pomeroy, D Cherbavaz, S Shak.
Abstract # 2285
ER and PR Assessment by Central IHC: Examination and Comparison of Percent Positive Cells and Nuclear Staining Intensity in ECOG Breast Cancer Study 2197
S Badve, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, S Shak, LJ Goldstein, GW Sledge, JA Sparano, FL Baehner
2008 San Antonio Breast Cancer Symposium (SABCS)-San Antonio, TX
Abstract # 25
GRB7-dependent pathways are potential therapeutic targets in triple-negative
breast cancer
Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker J, Shak S,
Badve S, Baehner FL, Perez EA, Shulman LN, Martino S, Sledge Jr. GW, Davidson
Abstract # 53
Risk of distant recurrence using oncotype DX in postmenopausal primary breast
cancer patients treated with anastrozole or tamoxifen: a TransATAC study
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R,
Baehner FL, Shak S, on Behalf of the ATAC Trialists' Group Royal Marsden Hospital,
London, United Kingdom; Wolfson Institute for Preventive Medicine, London, United
Kingdom; Newcastle Mater Hospital, Newcastle, Australia; Royal Infirmary, Glasgow,
United Kingdom; Genomic Health Institute, Redwood, CA
Abstract # 2066
Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in
situ that is adjacent to invasive ductal carcinoma
Baehner FL, Sangli C, Millward C, Cherbavaz D, Goddard A, Shak S Genomic Health,Inc, Redwood City, CA
Abstract # 3049
Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes
Henry NL, Shak S, Banerjee M, Skaar T, Palmer G, Braman M, Stearns V,Flockhart DA, Kleer C, Hayes DF, Rae J University of Michigan, Ann Arbor, MI; Genomic Health,Inc., Redwood City, CA; Indiana University, Indianapolis, IN; Johns Hopkins University,Baltimore, MD
2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium—Washington DC
Abstract #13
HER2 Concordance Between Central Laboratory Immunohistochemistry & Quantitative Reverse Transcription Polymerase Chain Reaction in Intergroup Trial E2197
FL Baehner, R Gray, B Childs, T Maddala, S Rowley, S Shak, NE Davidson, GW Sledge, LJ Goldstein, JA Sparano, S Badve
Abstract #41
HER2 Assessment in a Large Kaiser Permanente Case-Control Study: Comparison of Fluorescence In Situ Hybridization (FISH) and Quantitative Reverse Transcription Polymerase Chain Reaction (RTPCR) Performed by Central Laboratories
FL Baehner, Achacoso, T Maddala, C Alexander, S Shak, CP Quesenberry, LC Goldstein, AM Gown, LA Habel
Abstract #82: Oral Presentation
Analysis of Revised Nottingham Tumor Grade Constitutive Components and Recurrence Free Interval in ECOG Breast Cancer Study E2197
FL Baehner, LJ Goldstein, R Gray, T Maddala, S Shak, GW Sledge, JA Sparano, S Badve
Abstract #44: Poster Session
Comparison of ER and PR Assessment by Local IHC, Central IHC, and Central Quantitative RT-PCR in ECOG Breast Cancer Study 2197
S Badve, FL Baehner, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, LJ Goldstein, GW Sledge, JA Sparano
Abstract #47: Poster Session
A Kaiser-Permanente Population-Based Study of Breast Cancer ER and PR Expression by the Standard Method, Immunohistochemistry, Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction
FL Baehner, T Maddala, C Alexander, A Gown, LC Goldstein, y, S Shak, CP Quesenberry, L Habel
Abstract #50: Poster Session
Heterogeneity of Quantitative RT-PCR Measurement of Estrogen and Progesterone Receptor Expression: Comparison of Tissue Microarray Cores to Whole Sections of Paraffin Embedded Breast Cancer Tissue
FL Baehner, J Baker, J Salter, ML Liu, C Yoshizawa, T Maddala, M Dowsett, M Cronin, S Shak
2008 ASCO Annual Meeting―Chicago, IL
Abstract #557
Predictive Utility of Progesterone Receptor (PR) and Multigene Expression in Identifying Benefit From Adjuvant Doxorubicin Plus Cyclophosphamide (AC) or Docetaxel (AT) in Intergroup Trial E2197
LJ Goldstein, RJ Gray, R Bugarini, S Shak, SS Badve, FL Baehner, NE Davidson, GW Sledge, JA Sparano, The North American Breast Cancer Intergroup
2007 San Antonio Breast Cancer Symposium (SABCS)―San Antonio, TX
Abstract #10: Oral Presentation
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, ER-Positive Breast Cancer
K Albain, W Barlow, S Shak, G Hortobagyi, R Livingston, I Yeh, P Ravdin, C Yoshizawa, FL Baehner, N Davidson, G Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, C Allred, K Osborne, D Hayes
Abstract #63: Oral Presentation
Prognostic Utility of the 21-Gene Assay Compared with Adjuvant! in Hormone Receptor (HR) Positive Operable Breast Cancer with 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
L Goldstein, P Ravdin, R Gray, C Yoshizawa, B Childs, S Rowley, S Shak, S Badve, FL Baehner, N Davidson, GW Sledge, JA Sparano
Abstract #1043: Poster Session
Recurrence Score by Oncotype DX Evaluated on the Primary Breast Predicts the 2-Year Survival after First Relapse
G Bianchini, M Zambetti, P Mariani, A Moliterni, G Bianchi, G Mariani, A Fasolo, ML Carcangiu, P Valagussa, L Gianni
Abstract #1092: Poster Session
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score Assay on Patient Satisfaction, Anxiety and Decisional Conflict for Adjuvant Breast Cancer Treatment Selection
PB Mumby, SS Lo, J Norton, J Smerage, K Joseph, HK Chew, D Hayes, KS Albain
Abstract #2061: Poster Session
A Retrospective Analysis of the Impact of Oncotype DX Low Recurrence Score Results on Treatment Decisions in a Single Academic Breast Cancer Center
H Liang, AM Brufsky, BB Lembersky, P Rastogi, VG Vogel
Abstract #3028: Poster Session
Gene Expression by Standardized Quantitative RT-PCR in the Special Histologic Subtypes of Estrogen Receptor-Positive Invasive Breast Cancer
FL Baehner, D Watson, JT Ballard, G Palmer, S Shak
Abstract #3082: Poster Session
Evaluation of Practice Patterns in the Treatment of Node-Negative, Hormone-Receptor Positive Breast Cancer Patients with the Use of the Oncotype DX Assay at the University of Pennsylvania
C Erb, KR Fox, M Patel, K Hook, A DeMichele, C Kaplan, S Domchek
Abstract #5029: Poster Session
Estrogen Receptor and Breast Cancer Survival in a Kaiser Permanente Population-Based Study: Comparison of Quantitative Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry
LA Habel, N Achacoso, T Maddala, C Alexander, FL Baehner, S Shak, C Quesenberry, AM Gown, LC Goldstein
2007 ASCO Breast Cancer Symposium―San Francisco, CA
Abstract #27
Association of Individual Genes with Risk of Relapse in Operable Breast Cancer: Analysis of E2197
JA Sparano, L Goldstein, B Childs, C Yoshizawa, S Shak, J Baker, S Rowley, N Davidson, S Badve, GW Sledge Jr., R Gray
Abstract #87
ER and PR Assessment in ECOG 2197: Comparison of Locally Determined IHC with Centrally Determined IHC and Quantitative RT-PCR
SS Badve, FL Baehner, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, S Shak, GW Sledge Jr., JA Sparano
Abstract #88
A Kaiser-Permanente Population-Based Study of ER and PR Expression by the Standard Method, Immunohistochemistry (IHC), Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
FL Baehner, T Maddala, C Alexander, A Gown, LC Goldstein, NS Achacoso, S Shak, CP Quesenberry, LA Habel
Abstract #106
Use of Estrogen Receptor (ER) Expression by Quantitative RT-PCR to Identify an ER-Negative Subgroup by IHC Who Might Benefit from Hormonal Therapy
G Bianchini, M Zambetti, L Pusztai, M Carcangiu, P Valagussa, L Gianni
2007 ASCO Annual Meeting―Chicago, IL
Abstract #526: Poster Discussion
Prognostic Utility of the 21-Gene Assay in Hormone Receptor (HR)-Positive Operable Breast Cancer and 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
LJ Goldstein, R Gray, B Childs, D Watson, S Rowley, S Shak, S Badve, NE Davidson, GW Sledge, JA Sparano
Abstract #577: Poster Session
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score (RS) Assay on Medical Oncologist (MO) and Patient (PT) Adjuvant Breast Cancer (BC) Treatment Selection
SS Lo, J Norton, PB Mumby, J Smerage, J Kash, HK Chew, D Hayes, A Epstein, KS Albain
2007 American Association for Cancer Research (AACR) Annual Meeting―Los Angeles, CA
Abstract #4423: Poster Session
Optimized RNA Extraction and RT-PCR Provide Successful Molecular Analysis on a Variety of Archival Fixed Tissues
M Zhou, M Bronner, C Magi-Galluzzi, R Tuthill, FL Baehner, ML Liu, D Dutta, J Jeong, YT Chen, JR Hackett, M Cronin
2006 Association for Molecular Pathology (AMP) Annual Meeting―Orlando, FL
Poster ST23
Analytical Validation for the Oncotype DX Breast Cancer Assay, High Complexity, Multi-Analyte Molecular Diagnostic Test Service
M Cronin, C Sangli, ML Liu, M Pho, D Dutta, A Nguyen, J Jeong, J Wu, K Clark, D Watson
2006 SABCS―San Antonio, TX
Abstract #45: Oral Presentation
Quantitative RT-PCR Analysis of ER and PR by Oncotype DX Indicates Distinct and Different Associations with Prognosis and Prediction of Tamoxifen Benefit
FL Baehner, LA Habel, CP Quesenberry, A Capra, G Tang, S Paik, N Wolmark, D Watson, S Shak
Abstract #3116: Poster Presentation
A Comparison of Estrogen Receptor (ER) Measurement by Three Methods in Node-Negative, Estrogen Receptor (ER)-Positive Breast Cancer: Ligand Binding (LB), Immunohistochemistry (IHC), and Quantitative RT-PCR
C Kim, G Tang, FL Baehner, D Watson, JP Costantino, S Paik, S Shak, N Wolmark
Abstract #6039: Poster Presentation
The Impact on the Recurrence Score Due to Patient Variation in the Quantitative Expression of Individual Genes or Gene Groups
D Watson, G Palmer, J Baker, S Shak
Abstract #6111: Poster Presentation
Relationship Between Proliferation Genes and Expression of Hormone and Growth Factor Receptors: Quantitative RT-PCR in 10,618 Breast Cancers
S Shak, FL Baehner, G Palmer, JT Ballard, J Baker, D Watson
Abstract #6118: Poster Presentation
Subtypes of Breast Cancer Defined by Standardized Quantitative RT-PCR Analysis of 10,618 Tumors
S Shak, FL Baehner, G Palmer, JT Ballard, J Baker, D Watson
2006 ASCO Annual Meeting―Atlanta, GA
Abstract #538: Poster Discussion
Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded (FFPE) Core Biopsies Predict Docetaxel Chemosensitivity
JC Chang, A Makris, SG Hilsenbeck, JR Hackett, J Jeong, ML Liu, J Baker, K Sexton, CK Osborne, S Shak
Abstract #6024: Poster Discussion
21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Breast Cancer: An Economic Analysis Including Prognostic and Predictive Information
LE Cosler, NM Kuderer, J Hornberger, GH Lyman
2006 AACR Annual Meeting―Washington, DC
Abstract #3604: Poster Discussion
Multiple GSTM Gene Family Members Are Recurrence Risk Markers in Breast Cancer
M Kiefer, K Hoyt, J Hackett, MG Walker, J Baker
2005 SABCS―San Antonio, TX
Abstract #29: Oral Presentation
Association Between the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
E Mamounas, G Tang, J Bryant, S Paik, S Shak, JP Costantino, D Watson, DL Wickerham, N Wolmark
Abstract #310: Poster Discussion
Measurement of Gene Expression Using Tissue Microarray Cores of Paraffin-Embedded Breast Cancer Tissue
J Baker, J Salter, ML Liu, JR Hackett, M Cronin, S Shak, M Dowsett
Abstract #2049: Poster Session
Impact of Oncotype DX™ on Decision Making in Breast Cancer Clinical Practice
R Oratz, D Paul, A Cohn, S Sedlacek
2005 ASCO Annual Meeting―Orlando, FL
Abstract #510: Oral Presentation
Expression of the 21 Genes in the Recurrence Score Assay and Tamoxifen Clinical Benefit in the NSABP Study B-14 of Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
Abstract #603: Poster Session
Gene Expression and Breast Cancer Mortality in Northern California Kaiser Permanente Patients: A Large Population-Based Case Control Study
LA Habel, CP Quesenberry, M Jacobs, D Greenberg, L Fehrenbacher, C Alexander, J Baker, D Watson, J Hackett, S Shak
2004 SABCS―San Antonio, TX
Abstract #24: Oral Presentation
Expression of the 21 Genes in the Recurrence Score Assay and Prediction of Clinical Benefit from Tamoxifen in NSABP Study B-14 and Chemotherapy in NSABP Study B-20
S Paik, S Shak, G Tang, C Kim, H Joo, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
Abstract #104: Poster Discussion
Risk Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based on Patient Age, Tumor Size, and Tumor Grade
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, J Bryant, N Wolmark
Abstract #2081: Poster Discussion
A 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC): An Age-Specific Economic Analysis
GH Lyman, L Cosler, J Hornberger
2004 ASCO Annual Meeting―New Orleans, LA
Abstract #501: Oral Presentation
Gene Expression Profiles of Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Patients with Locally Advanced Breast Cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, G Mariani, J Rodriguez, M Carcangiu, D Watson, P Valagussa, S Shak
Abstract #6036: Poster Session
Economic Analysis of Targeting Chemotherapy (CT) Using a 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC)
LE Cosler, J Hornberger, GH Lyman
2004 USCAP Annual Meeting―Vancouver, British Columbia
Abstract #83
Comparison of ER, PR, HER2, and Ki-67 Quantitative Expression in Formalin-Fixed, Paraffin-Embedded Breast Carcinomas by RT-PCR with Protein Expression by Immunohistochemistry
P Bitterman, D Watson, M Cronin, JM Mosquera, M Cobleigh, R Baehner, S Shak, J Baker
Abstract #80
Use of Macrodissection in Multi-Gene RNA Analysis of Fixed Paraffin- Embedded Tumor Tissue
R Baehner, B Hiller, CY Kim, C Alexander, ML Liu, M Pho, D Dutta, J Jeong, A Nguyen, M Walker, M Cronin, J Baker, S Paik
Abstract #1491
Reproducibility of Quantitative Gene Expression Analysis by a New RT-PCR Assay Using Fixed Paraffin-Embedded Tissues: A Molecular Tomographic Scanning Study
M Cronin, D Watson, D Dutta, ML Liu, M Pho, R Baehner, J Esteban, J Baker, S Shak
2003 SABCS―San Antonio, TX
Abstract #16: Oral Presentation
Multi-Gene RT-PCR Assay for Predicting Recurrence in Node-Negative Breast Cancer Patients - NSABP Studies B-20 and B-14
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, DWatson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
Abstract #17: Oral Presentation
Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
FJ Esteva, AA Sahin, M Cristofanilli, K Coombes, SJ Lee, J Baker, M Cronin, MG Walker, D Watson, S Shak, GN Hortobagyi
2003 ASCO Annual Meeting―Chicago, IL
Abstract #3415: Poster Session
Tumor Gene Expression Predicts Distant Disease-Free Survival (DDFS) in Breast Cancer Patients with 10 or More Positive Nodes: High Throughput RT-PCR Assay of Paraffin-Embedded Tumor Tissues
MA Cobleigh, P Bitterman, J Baker, M Cronin, ML Liu, R Borchik, B Tabesh, J Mosquera, MG Walker, S Shak
Abstract #3416: Poster Discussion
Tumor Gene Expression and Prognosis in Breast Cancer: Multi-Gene RT-PCR Assay of Paraffin-Embedded Tissue
JM Esteban, J Baker, M Cronin, ML Liu, MG Llamas, MG Walker, R Mena, S Shak
Abstract #3466: Poster Session
Predicting Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer: Gene Expression Profiling of Paraffin-Embedded Core Biopsy Tissue
SE Soule, S Shak, J Baker, M Cronin, ML Liu, S Badve, KD Miller, GW Sledge
2003 AACR Oncogenomics Meeting―Phoenix, AZ
Poster Session
Gene Expression Profiling of Fixed, Paraffin-Embedded Tumor Specimens, Using a 192 Gene Panel RT-PCR Assay
M Kiefer, J Stephans, ML Liu, D Dutta, M Pho, A Nguyen, J Jeong, M Cronin, JM Esteban
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Strategies to Optimize Anti-Receptor Therapies
J Baselga
2002 ASCO Annual Meeting―Orlando, FL
Abstract #3017
Gene Expression Profiling of Fixed Paraffin-Embedded Breast Cancer Tissues
M Kiefer, J Stephans, S Abulaban, S Shodhan, MC Alexander, JM Esteban